Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran

Nasri, Elahe; Shoaei, Parisa; Vakili, Bahareh; Mirhendi, Hossein; Sadeghi, Somayeh; Hajiahmadi, Somayeh; Sadeghi, Alireza; Vaezi, Afsane; Badali, Hamid; Fakhim, Hamed

doi:10.1007/s11046-020-00493-2

Cited by 33 publications

(26 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A. niger , A. terreus , A. lentulus , A. nidulans , A. awamori , A. penicillioides , and A. citrinoterreus [ 23 , 56 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 ]. The most used diagnostic methods were cultivation, galactomannan and (1,3)-β-D-glucan detection, MALDI-TOF, histopathology, serological tests, PCR, and sequencing [ 23 , 56 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , …”

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

“…It should be noted that in some of the A. fumigatus isolates, the TR34/L98H mutation in the Cyp51A gene was detected, which is associated with environmental azole resistance to antifungal agents [ 78 , 83 ]. Caspofungin, voriconazole, amphotericin B, anidulafungin, posaconazole, itraconazole, fluconazole or isavuconazole were used in antifungal treatment [ 23 , 56 , 62 , 63 , 64 , 66 , 67 , 69 , 70 , 71 , 72 , 74 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 84 , 85 , 86 , 87 , 88 , 89 , 90 ].…”

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

“…The fatality rate in cases of Aspergillus co-infection with SARS-CoV-2 was between 13% and 100% [ 23 , 56 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 ]. The affected patients were mainly men between 42 and 87 years of age [ 23 , 56 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 ,…”

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

“…The affected patients were mainly men between 42 and 87 years of age [ 23 , 56 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 ]. The reported predisposing risk factors for the mycosis progression were diverse, including treatment with corticosteroids or immunosuppressants, hospitalization in the ICU, diabetes mellitus, hypertension, obesity, invasive mechanical ventilation, neoplasms, chronic obstructive pulmonary disease (COPD), asthma, and kidney disease [ 23 , 56 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 <...>…”

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

See 3 more Smart Citations

Epidemiology of Systemic Mycoses in the COVID-19 Pandemic

Frías-De-León

Pinto‐Almazán

Hernández‐Castro

et al. 2021

JoF

View full text Add to dashboard Cite

The physiopathologic characteristics of COVID-19 (high levels of inflammatory cytokines and T-cell reduction) promote fungal colonization and infection, which can go unnoticed because the symptoms in both diseases are very similar. The objective of this work was to study the current epidemiology of systemic mycosis in COVID-19 times. A literature search on the subject (January 2020–February 2021) was performed in PubMed, Embase, Cochrane Library, and LILACS without language restrictions. Demographic data, etiological agent, risk factors, diagnostic methods, antifungal treatment, and fatality rate were considered. Eighty nine publications were found on co-infection by COVID-19 and pneumocystosis, candidiasis, aspergillosis, mucormycosis, coccidioidomycosis, or histoplasmosis. In general, the co-infections occurred in males over the age of 40 with immunosuppression caused by various conditions. Several species were identified in candidiasis and aspergillosis co-infections. For diagnosis, diverse methods were used, from microbiological to molecular. Most patients received antifungals; however, the fatality rates were 11–100%. The latter may result because the clinical picture is usually attributed exclusively to SARS-CoV-2, preventing a clinical suspicion for mycosis. Diagnostic tests also have limitations beginning with sampling. Therefore, in the remainder of the pandemic, these diagnostic limitations must be overcome to achieve a better patient prognosis.

show abstract

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

Section: Aspergillosis and Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Epidemiology of Systemic Mycoses in the COVID-19 Pandemic

Frías-De-León

Pinto‐Almazán

Hernández‐Castro

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…32 A fatal case of probable IPA in a patient with acute myeloid leukemia patient infected with SARS-CoV-2 who developed ARDS was reported in Iran. 30 By June 2020, the prevalence of IPA among patients with COVID-19 admitted to ICUs in the Netherlands, France, and Germany was 19.4%, 33%, and 26%, respectively. 31,32 Reports from China indicate that fungal co-infections, including aspergillosis, occur in at least 10% of patients hospitalized with ARDs in ICUs.…”

Section: Aspergillosis In Patients With Covid-19mentioning

confidence: 99%

Predisposing factors of important invasive fungal coinfections in COVID-19 patients: a review article

Zia

Goli

2021

J Int Med Res

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 has caused a devastating pandemic lasting for more than a year. To date, 47 million individuals have been infected and 1.2 million individuals have died worldwide. Some of the most important coinfections in patients with coronavirus disease 2019 (COVID-19) are opportunistic invasive fungal infections (OIFIs), which are sometimes not rapidly diagnosed and are often diagnosed after death. Aspergillosis and candidiasis are the most prevalent OIFIs in patients with COVID-19. Mycormycosis, cryptococcosis, and other fungal diseases have also been documented more rarely. This review aimed to summarize factors affecting COVID-19 transmission, prevalence, morbidity, and mortality in Iran as well as to review common OIFIs in patients with COVID-19. Immunological factors, underlying diseases, and social, cultural, and environmental factors can affect COVID-19 transmission. There is a need to improve diagnostic and therapeutic criteria for OIFIs and to optimize management procedures so that patients with OIFIs can receive treatment as rapidly as possible. Screening of patients with confirmed COVID-19 for OIFIs at the treating physician’s discretion could enable early OIFI diagnosis, treatment, and mortality reduction.

show abstract